We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Mitral Valve Repair During Bypass Surgery Could Improve Heart Function

By HospiMedica International staff writers
Posted on 15 Mar 2012
Mitral valve repair (MVR) during coronary artery bypass graft (CABG) surgery benefits ischemic heart disease patients, according to a new study. More...


Researchers at Imperial College (London, United Kingdom) randomized 60 patients with moderate functional ischemic mitral regurgitation (FIMR) to receive CABG only or dual procedures CABG and MVR annuloplasty; all patients had moderate mitral valve leaks caused by their ischemic heart disease. The researchers examined the patients' exercise capacity, heart function, and heart size, both before and one year after surgery.

The researchers found that in the year after surgery, the patients who had MVR and CABG improved 3 mL/kg/min in exercise capacity, compared to 1 mL/kg/min in patients who only had CABG. Heart size was reduced by 24% in the dual-procedure patients, versus 10% in the CABG-only group. Blood levels of plasma brain natriuretic peptide (pBNP, which is increased when the heart muscle is over-stretched or in heart failure) was lower in those who had the dual procedure (54.8 pmol/L) compared to those with CABG only (108.9 pmol/L). The study was presented as an American Heart Association (AHA) Emerging Science Series webinar, held during February 2012 in Dallas (TX, USA).

“The majority of these patients come to surgery not because of the mitral regurgitation but for revascularization of their ischemic coronary disease, and by convention, if the mitral regurgitation has not been severe, a lot of surgeons attempt just to revascularize,” said lead author and webinar presenter Kok Meng John Chan, MD. “But we have increasing evidence that [mitral regurgitation] is not a benign condition and that even moderate degrees of ischemic mitral regurgitation are significant.”

Current AHA guidelines give MVR in patients with ischemic mitral regurgitation undergoing CABG a class IIa (level of evidence B) recommendation. The researchers believe that the study and several more ongoing studies will eventually push that to a class I recommendation.

Related Links:
Imperial College


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.